KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Total Liabilities (2020 - 2025)

Historic Total Liabilities for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $352.6 million.

  • Recursion Pharmaceuticals' Total Liabilities rose 7459.54% to $352.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $352.6 million, marking a year-over-year increase of 7459.54%. This contributed to the annual value of $413.8 million for FY2024, which is 11749.68% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Total Liabilities stood at $352.6 million for Q3 2025, which was up 7459.54% from $383.2 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Total Liabilities ranged from a high of $413.8 million in Q4 2024 and a low of $55.9 million during Q2 2021
  • Its 5-year average for Total Liabilities is $210.7 million, with a median of $197.7 million in 2023.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Total Liabilities skyrocketed by 32489.32% in 2022 and then crashed by 2053.59% in 2024.
  • Over the past 5 years, Recursion Pharmaceuticals' Total Liabilities (Quarter) stood at $67.4 million in 2021, then soared by 219.67% to $215.5 million in 2022, then decreased by 11.7% to $190.3 million in 2023, then skyrocketed by 117.5% to $413.8 million in 2024, then dropped by 14.8% to $352.6 million in 2025.
  • Its last three reported values are $352.6 million in Q3 2025, $383.2 million for Q2 2025, and $371.3 million during Q1 2025.